Assembly Biosciences Shares Rise on Results from Hepatitis B Drug Trial

Dow Jones

Dec 26, 2024

By Dean Seal

Shares of Assembly Biosciences advanced after the company reported encouraging results from a clinical trial of its treatment for the hepatitis B virus.

The stock was up 5.2% at $15.49 in premarket trading. Shares have risen 50% since the start of the year.

The biotechnology company said Thursday that in its ongoing Phase 1b study, a 150 milligram dose of ABI-4334 showed strong antiviral activity and a mean reduction in plasma hepatitis B virus DNA over 28 days of treatment.

ABI-4334 was well-tolerated, with a favorable safety profile and a half-life that supports once-daily oral dosing, Assembly said.

Enrollment for a final cohort of patients dosed with 400 milligrams of ABI-4334 is expected in the first half of 2025.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

December 26, 2024 09:00 ET (14:00 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2494186393"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2494186393\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2494186393?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-26 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494186393","market":"nz","top_or_hot":-1,"title":"Assembly Biosciences Shares Rise on Results from Hepatitis B Drug Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     By Dean Seal \n</p>\n<p>\n  Shares of Assembly Biosciences advanced after the company reported encouraging results from a clinical trial of its treatment for the hepatitis B virus. \n</p>\n<p>\n  The stock was up 5.2% at $15.49 in premarket trading. Shares have risen 50% since the start of the year. \n</p>\n<p>\n  The biotechnology company said Thursday that in its ongoing Phase 1b study, a 150 milligram dose of ABI-4334 showed strong antiviral activity and a mean reduction in plasma hepatitis B virus DNA over 28 days of treatment. \n</p>\n<p>\n  ABI-4334 was well-tolerated, with a favorable safety profile and a half-life that supports once-daily oral dosing, Assembly said. \n</p>\n<p>\n  Enrollment for a final cohort of patients dosed with 400 milligrams of ABI-4334 is expected in the first half of 2025. \n</p>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 26, 2024 09:00 ET (14:00 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assembly Biosciences Shares Rise on Results from Hepatitis B Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssembly Biosciences Shares Rise on Results from Hepatitis B Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-26 22:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     By Dean Seal \n</p>\n<p>\n  Shares of Assembly Biosciences advanced after the company reported encouraging results from a clinical trial of its treatment for the hepatitis B virus. \n</p>\n<p>\n  The stock was up 5.2% at $15.49 in premarket trading. Shares have risen 50% since the start of the year. \n</p>\n<p>\n  The biotechnology company said Thursday that in its ongoing Phase 1b study, a 150 milligram dose of ABI-4334 showed strong antiviral activity and a mean reduction in plasma hepatitis B virus DNA over 28 days of treatment. \n</p>\n<p>\n  ABI-4334 was well-tolerated, with a favorable safety profile and a half-life that supports once-daily oral dosing, Assembly said. \n</p>\n<p>\n  Enrollment for a final cohort of patients dosed with 400 milligrams of ABI-4334 is expected in the first half of 2025. \n</p>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 26, 2024 09:00 ET (14:00 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ASMB","symbol_name":"Assembly Biosciences Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2494186393","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494186393","pubTimestamp":1735221600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Assembly Biosciences advanced after the company reported encouraging results from a clinical trial of its treatment for the hepatitis B virus.The stock was up 5.2% at $15.49 in premarket trading. Shares have risen 50% since the start of the year.The biotechnology company said Thursday that in its ongoing Phase 1b study, a 150 milligram dose of ABI-4334 showed strong antiviral activity and a mean reduction in plasma hepatitis B virus DNA over 28 days of treatment.ABI-4334 was well-tolerated, with a favorable safety profile and a half-life that supports once-daily oral dosing, Assembly said.Enrollment for a final cohort of patients dosed with 400 milligrams of ABI-4334 is expected in the first half of 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ASMB":"Assembly Biosciences Inc.","BK4139":"生物科技"},"translate_title":"Assembly Biosciences股价因乙型肝炎药物试验结果而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASMB":1},"content_text":"By Dean Seal \n\n\n  Shares of Assembly Biosciences advanced after the company reported encouraging results from a clinical trial of its treatment for the hepatitis B virus. \n\n\n  The stock was up 5.2% at $15.49 in premarket trading. Shares have risen 50% since the start of the year. \n\n\n  The biotechnology company said Thursday that in its ongoing Phase 1b study, a 150 milligram dose of ABI-4334 showed strong antiviral activity and a mean reduction in plasma hepatitis B virus DNA over 28 days of treatment. \n\n\n  ABI-4334 was well-tolerated, with a favorable safety profile and a half-life that supports once-daily oral dosing, Assembly said. \n\n\n  Enrollment for a final cohort of patients dosed with 400 milligrams of ABI-4334 is expected in the first half of 2025. \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  December 26, 2024 09:00 ET (14:00 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}